Tearsheet

Sarepta Therapeutics (SRPT)


Market Price (10/20/2025): $22.5 | Market Cap: $2.2 Bil
Sector: Health Care | Industry: Biotechnology

Sarepta Therapeutics (SRPT)


Market Price (10/20/2025): $22.5
Market Cap: $2.2 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow


0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 65%
Weak multi-year price returns
2Y Excs Rtn is -135%, 3Y Excs Rtn is -166%
Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -0.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 0.0%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -93%
  Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -12%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -18%
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.2%
3   Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 20%
0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 65%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -93%
2 Weak multi-year price returns
2Y Excs Rtn is -135%, 3Y Excs Rtn is -166%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -0.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 0.0%
4 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -12%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -18%
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -7.2%
6 Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 20%

Market Valuation & Key Metrics

SRPT Stock


Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
SRPT Return32%-47%44%-26%26%-81%-83%
Peers Return115%28%-1%-14%-26%68%193%
S&P 500 Return16%27%-19%24%23%13%106%

Monthly Win Rates [3]
SRPT Win Rate42%50%83%50%58%22% 
Peers Win Rate56%50%52%40%35%61% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
SRPT Max Drawdown-36%-61%-30%-48%-3%-90% 
Peers Max Drawdown-32%-20%-36%-39%-41%-31% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: ALNY, IONS, MRNA, ARWR, ACSB. See SRPT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/17/2025 (YTD)

Downturns Compared

Unique KeyEventSRPTS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-63.2%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven172.0%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-37.4%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven59.8%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven54 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-54.9%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven121.8%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven265 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-85.0%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven566.7%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1385 days1480 days


How Low Can It Go?

Sarepta Therapeutics's stock fell -63.2% during the 2022 Inflation Shock from a high on 1/1/2021. A -63.2% loss requires a 172.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Better Bets than Sarepta Therapeutics (SRPT)

Trade Ideas

Select past ideas related to SRPT. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
-2.0%-2.0%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
4.3%4.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
11.2%11.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
-4.4%-4.4%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
-2.0%-2.0%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
2.8%2.8%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
4.3%4.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
11.2%11.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
-4.4%-4.4%-8.0%

Recent Active Movers

Recent Active Movers

More From Trefis

Peer Comparisons for Sarepta Therapeutics

Financials

SRPTALNYIONSMRNAARWRACSBMedian
NameSarepta .Alnylam .Ionis Ph.Moderna Arrowhea.Acesis  
Mkt Price22.51481.6773.0926.0136.81-36.81
Mkt Cap2.262.511.610.15.1-10.1
Rev LTM2,4822,3487173,055573-2,348
Op Inc LTM-1-115-472-3,273-108--115
FCF LTM-454-75-563-3,500-18--454
FCF 3Y Avg-505-184-438-2,744-298--438
CFO LTM-301-45-502-2,69722--301
CFO 3Y Avg-395-131-401-2,055-175--395

Growth & Margins

SRPTALNYIONSMRNAARWRACSBMedian
NameSarepta .Alnylam .Ionis Ph.Moderna Arrowhea.Acesis  
Rev Chg LTM64.9%17.2%-7.6%-38.8%2,816.2%-17.2%
Rev Chg 3Y Avg45.0%40.8%-1.4%-48.0%908.8%-40.8%
Rev Chg Q68.4%20.2%10.1%-38.0%--15.2%
QoQ Delta Rev Chg LTM11.1%4.4%1.7%-2.7%5.1%-4.4%
Op Mgn LTM-0.0%-4.9%-65.9%-107.1%-18.8%--18.8%
Op Mgn 3Y Avg-16.1%-27.5%-65.7%-65.1%-958.1%--65.1%
QoQ Delta Op Mgn LTM5.2%3.0%1.5%11.7%2.9%-3.0%
CFO/Rev LTM-12.1%-1.9%-70.0%-88.3%3.8%--12.1%
CFO/Rev 3Y Avg-29.1%-13.1%-59.0%-51.8%-620.8%--51.8%
FCF/Rev LTM-18.3%-3.2%-78.5%-114.6%-3.1%--18.3%
FCF/Rev 3Y Avg-35.5%-16.6%-64.4%-67.2%-949.2%--64.4%

Valuation

SRPTALNYIONSMRNAARWRACSBMedian
NameSarepta .Alnylam .Ionis Ph.Moderna Arrowhea.Acesis  
Mkt Cap2.262.511.610.15.1-10.1
P/S0.926.616.23.38.9-8.9
P/EBIT-440.6-297.2-30.7-3.4-68.2--68.2
P/E-38.1-231.6-25.3-3.5-34.5--34.5
P/CFO-7.3-1,384.6-23.1-3.7234.3--7.3
Total Yield-2.6%-0.4%-3.9%-28.8%-2.9%--2.9%
Dividend Yield0.0%0.0%0.0%0.0%0.0%-0.0%
FCF Yield 3Y Avg-12.0%-0.8%-7.0%-14.3%-8.8%--8.8%
D/E0.60.00.10.10.1-0.1
Net D/E0.3-0.0-0.1-0.4-0.1--0.1

Returns

SRPTALNYIONSMRNAARWRACSBMedian
NameSarepta .Alnylam .Ionis Ph.Moderna Arrowhea.Acesis  
1M Rtn29.1%6.2%19.8%3.1%19.9%-19.8%
3M Rtn59.9%50.3%75.0%-16.8%119.6%-59.9%
6M Rtn-58.2%105.4%157.4%5.2%227.5%-105.4%
12M Rtn-82.3%62.8%84.2%-51.9%73.8%-62.8%
3Y Rtn-79.9%149.6%63.0%-78.0%12.9%-12.9%
1M Excs Rtn21.1%6.0%17.9%1.7%16.3%-16.3%
3M Excs Rtn63.3%44.6%70.2%-21.7%144.6%-63.3%
6M Excs Rtn-84.3%79.2%131.2%-20.9%201.3%-79.2%
12M Excs Rtn-96.4%53.0%78.6%-69.2%70.6%-53.0%
3Y Excs Rtn-166.2%73.9%-27.5%-166.4%-71.3%--71.3%

Financials

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Phosphorodiamidate morpholino oligomer (PMO) Products945844   
ELEVIDYS2000   
Collaboration and Other98898984 
AMONDYS 45  900 
EXONDYS 51  454422 
VYONDYS 53  6934 
Products, net    381
Total1,243933702540381


Price Behavior

Short Interest

Short Interest: As Of Date9302025
Short Interest: Shares Quantity19,618,972
Short Interest: % Change Since 9152025-3.2%
Average Daily Volume6,042,788
Days-to-Cover Short Interest3.25
Basic Shares Quantity98,005,000
Short % of Basic Shares20.0%

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/16/202519.5%-27.5%10.4%
1/13/20250.3%-1.4%-7.3%
1/8/202416.7%12.5%22.8%
1/9/20231.4%10.6%3.3%
1/10/2022-10.9%-16.8%-11.8%
10/15/2021-3.5%-4.7%-0.4%
1/11/20219.1%9.8%13.2%
1/13/2020-3.4%-0.9%-3.9%
SUMMARY STATS   
# Positive534
# Negative354
Median Positive9.1%10.6%11.8%
Median Negative-3.5%-4.7%-5.6%
Max Positive19.5%12.5%22.8%
Max Negative-10.9%-27.5%-11.8%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025806202510-Q 6/30/2025
3312025506202510-Q 3/31/2025
12312024228202510-K 12/31/2024
93020241106202410-Q 9/30/2024
6302024807202410-Q 6/30/2024
3312024501202410-Q 3/31/2024
12312023228202410-K 12/31/2023
93020231101202310-Q 9/30/2023
6302023802202310-Q 6/30/2023
3312023502202310-Q 3/31/2023
12312022228202310-K 12/31/2022
93020221102202210-Q 9/30/2022
6302022802202210-Q 6/30/2022
3312022504202210-Q 3/31/2022
12312021301202210-K 12/31/2021
93020211103202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value
Value of
Held Shares
Form
0Boor Kathryn Jean 12062024Sell125.551,636205,400738,234Form